Immunovant (IMVT) News & Sentiment

Immunovant stock down on dismal third-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.

NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported financial results for its fiscal third quarter ended December 31, 2024.

NEW YORK , Jan. 24, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.

The year started off slow as far as insider purchases go.

IMVT reports dismal second-quarter fiscal 2025 results. It is on track to initiate several studies on IMVT-1402 across various autoimmune indications.

Immunovant stock rises on mid-stage study data of batoclimab for Graves' Disease, showing superior efficacy compared to anti-thyroid drug therapy options.

NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported positive results from the Phase 2a trial of batoclimab in Graves' Disease. Immunovant also disclosed data from several proprietary market research studies that showed a consistent unmet need among ATD treated patients who are intolerant to, uncontrolled on or relapsed after ATDs. Finally, Immunovant also announced alignment with the U.S. Food & Drug Administration (FDA) and Investigational New Drug Application (IND) clearance with initiation of a pivotal trial of IMVT-1402 in GD expected by December 31, 2024.

Monday, Immunovant, Inc. IMVT reported results from the Phase 2a trial of batoclimab in Graves' Disease, an immune system condition that affects the thyroid gland. It causes the body to make too much thyroid hormone.

NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fourth quarter and fiscal year ended March 31, 2024.